- Home
- RDZN vs SWKH Comparison
RDZN vs SWKH Comparison
Compare RDZN & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RDZN | SWKH |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | 308 | 9 |
| Industry | Blank Checks | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 198.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RDZN | SWKH |
|---|---|---|
| Price | $1.71 | $15.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 618.3K | 104.8K |
| Earning Date | 02-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.77 | N/A |
| Revenue Next Year | $51.46 | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $13.91 |
| 52 Week High | $2.56 | $17.90 |
Technical Indicators
Market Signals| Indicator | RDZN | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 32.19 |
| Support Level | $1.60 | $14.69 |
| Resistance Level | $1.99 | $17.08 |
| Average True Range (ATR) | 0.14 | 0.37 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 8.82 | 12.06 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.